Fertility preservation in patients receiving chemotherapy or radiotherapy
- PMID: 25438367
- PMCID: PMC6172082
Fertility preservation in patients receiving chemotherapy or radiotherapy
Abstract
The preservation and restoration of fertility are key aspects for enhancing quality of life in cancer survivors. Cytotoxic agents and radiation can produce gonadal dysfunction in both men and women. Survival rates for cancers that occur before or during reproductive age have improved dramatically. Current fertility preservation options are available but limited in males and females. Referral to a reproductive endocrinologist around the time of diagnosis is important to optimize treatment options.
Figures
References
-
- Revel A, Revel-Vilk S. Pediatric fertility preservation: is it time to offer testicular tissue cryopreservation? Mol Cell Endocrinology. 2008;282:143–149. - PubMed
-
- Oehniger S. Strategies for fertility preservation and male cancer survivors. J Soc Gynecol Investig. 2005;12(4):222–31. - PubMed
-
- Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, El-Nashar SA, Al-Inany HG, Falcone T. Gonadotropin-releasing hormone and analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systemic review and meta-analysis. Fertil Steril. 2011;95(3):906–914. - PubMed
-
- The Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil Steril. 2010;100:1224–31. - PubMed
-
- Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors’ attitudes and experiences. Cancer. 1999;86(4):697–709. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical